Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin/Pioglitazone FDC Bioavailability Study
NCT02183636Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2009
- Primary completion
- Dec 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of linagliptin from 0 to 72 hours, Maximum measured concentration of linagliptin at 120 hours and 2 more. Started Aug 2009; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02183636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183636.